西洛他唑对下肢血运重建后保肢疗效的文献综述与荟萃分析
本研究通过荟萃分析4项随机对照试验和6项回顾性队列研究,纳入3136例下肢外周动脉疾病血运重建患者,评估西洛他唑对比标准抗血小板治疗的效果。结果显示西洛他唑改善无截肢生存、保肢率、减少再血管化和再狭窄,但不影响全因死亡率,对伤口愈合的影响不一致。
要点
- 西洛他唑改善无截肢生存(HR 0.79)和保肢率(HR 0.42)。
- 西洛他唑减少再次血运重建(RR 0.44)和再狭窄(RR 0.68)。
- 西洛他唑对全因死亡率无差异,伤口愈合证据不一致。
核心结论
- 西洛他唑对晚期外周动脉疾病和 критическая肢体缺血患者血运重建后的肢体相关和动脉通畅相关结局有益,但对全因死亡率无影响。
研究设计与样本
- 荟萃分析纳入4项随机对照试验和6项回顾性队列研究,共3136例患者,随访平均2年。
主要发现
- 西洛他唑组无截肢生存HR 0.79(95%CI 0.69-0.91),保肢率HR 0.42(95%CI 0.27-0.66)。
- 西洛他唑组再次血运重建RR 0.44(95%CI 0.37-0.52),再狭窄RR 0.68(95%CI 0.61-0.76)。
- 西洛他唑组免于靶病变血运重建RR 1.35(95%CI 1.21-1.53),全因死亡率无差异。
关键数值与推荐
- 患者年龄范围53至83岁,男性占66%,超过50%符合 критическая肢体缺血定义(Rutherford class ≥4)。
临床怎么用
- 对于下肢外周动脉疾病血运重建患者,可考虑西洛他唑以改善保肢和减少再狭窄,但需个体化评估。
局限性
- 伤口愈合结局不一致,需进一步研究评估西洛他唑对晚期外周动脉疾病患者伤口愈合的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current clinical guidelines recommend the use of cilostazol in the treatment of patients with infrainguinal peripheral artery disease (PAD) who experience intermittent claudication. However, the role of cilostazol therapy in patients with advanced PAD and critical limb ischemia (CLI) remains unclear. To conduct a meta-analysis of randomized controlled trials and cohort studies that evaluated the effect of cilostazol vs standard antiplatelet therapy on limb-related and arterial patency-related outcomes. We also reviewed literature pertinent to the effect of cilostazol on wound healing in patients with advanced PAD. METHODS: We performed a MEDLINE, EMBASE, COCHRANE (CENTRAL), SCOPUS, and US Clinical Trials database search for all trials and studies since 1999 that compared cilostazol with standard antiplatelet therapy in the setting of infrainguinal PAD revascularization procedures (endovascular or open). Aggregate data was collected from four randomized control trials and six retrospective cohort studies. The end point incidence ratios and treatment effects were generated from each study and reported as hazard ratios (HR) using a random-effect model. We also reviewed 10 studies that evaluated the effect of cilostazol on wound healing in patients with advanced PAD. RESULTS: From more than 25,000 total patients, 3136 patients met our inclusion criteria. All patients had at least lifestyle-impacting intermittent claudication, and more than 50% met the definition of CLI (Rutherford class ≥4). Patient age range was 53 to 83 years, and the majority were male (66%). The mean follow-up time averaged 2 years across all studies. Meta-analysis revealed that cilostazol treatment favored amputation-free survival (hazard ratio [HR], 0.79; 95% confidence interval [CI], 0.69-0.91), limb salvage rate (HR, 0.42; 95% CI, 0.27-0.66), decreased repeat revascularization (risk ratio [RR], 0.44; 95% CI, 0.37-0.52), and decreased restenosis (RR, 0.68; 95% CI, 0.61-0.76). Cilostazol treatment also increased freedom from target lesion revascularization (RR, 1.35; 95% CI, 1.21-1.53) with no difference in all-cause mortality. Effective wound healing was found to be an inconsistent outcome measure in patients receiving cilostazol therapy. CONCLUSIONS: We observed that cilostazol therapy has a beneficial impact on all limb-related and arterial patency-related outcomes, but no effect on all-cause mortality in patients with advanced PAD and CLI undergoing revascularization procedures. Additional studies are needed to evaluate the effect of cilostazol therapy on wound healing in patients with advanced PAD.
引用
- Desai K, Han B, Kuziez L, et al. Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization. J Vasc Surg. 2020. PMID: 32891809. doi:10.1016/j.jvs.2020.08.125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。